Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | LABMT: impact of treatment prior to allogenic HCT in MDS

Fernando Barroso Duarte • 30 Aug 2020
EBMT 2020
Myelodysplastic Syndromes

Fernando Barroso Duarte, MD, Federal University of Ceara, Clinical Hospital, Fortaleza, Brazil discusses the results of the Latin American Bone Marrow Transplant (LABMT) registry on the impact of treatment prior to allogeneic hematopoietic cell transplantation (HCT) in myelodysplastic syndromes (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Fernando Barroso Duarte

6:04
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
Fernando Barroso Duarte • 12 May 2023
3:31
Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era
Fernando Barroso Duarte • 13 Feb 2023
4:11
Expanding access to stem cell transplantation & CAR-T therapy in Latin America
Fernando Barroso Duarte • 13 Feb 2023
2:26
Aims & activity of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO)
Fernando Barroso Duarte • 13 Feb 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals